adenine has been researched along with Cholera Infantum in 12 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study assessed the antiviral efficacy and safety of tenofovir disoproxil fumarate (TDF) for up to 12 months in Korean treatment-naïve chronic hepatitis B (CHB) patients." | 7.80 | Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort. ( Ahn, SH; Ahn, SS; Chon, YE; Han, KH; Kim, BK; Kim, DY; Kim, SU; Park, JY, 2014) |
| " This article describes results from the CASTLE study (comparing once-daily atazanavir/ritonavir [ATV/RTV] with twice-daily lopinavir/ritonavir [LPV/RTV], both in combination with fixed-dose tenofovir/emtricitabine, in treatment-naive HIV-infected patients) and an evaluation of the impact of gastrointestinal (GI) complications of treatment on patient QoL, as measured by the irritable bowel syndrome (IBS) QoL questionnaire (IBS-QoL)." | 5.14 | Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study. ( Absalon, J; Malan, N; Mancini, M; McGrath, D; Su, J; Wirtz, V; Yang, R, 2010) |
| "This study assessed the antiviral efficacy and safety of tenofovir disoproxil fumarate (TDF) for up to 12 months in Korean treatment-naïve chronic hepatitis B (CHB) patients." | 3.80 | Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort. ( Ahn, SH; Ahn, SS; Chon, YE; Han, KH; Kim, BK; Kim, DY; Kim, SU; Park, JY, 2014) |
| " Most common adverse events (AEs) leading to prior KI discontinuation were rash (27%), arthralgia (18%), and atrial fibrillation (16%)." | 3.01 | Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy. ( Barr, PM; Barrientos, JC; Brander, DM; Cheson, BD; Dorsey, C; Flinn, IW; Fonseca, GA; Ghosh, N; Hamadeh, IS; Kambhampati, S; Lamanna, N; Lansigan, F; LaRatta, N; Luning Prak, ET; Mato, AR; Miskin, HP; Pagel, JM; Paskalis, D; Pu, JJ; Rai, KR; Reeves, JA; Roeker, L; Schuster, SJ; Sitlinger, A; Skarbnik, AP; Sportelli, P; Svoboda, J; Tsao, P; Weiss, MS; Weissbrot, H, 2021) |
| "After minimal residual disease-guided treatment (day 1 of month 16), 84 (62%, 90% CI 55-69) of 135 patients (ITT population) achieved a complete response with bone marrow minimal residual disease of less than 0·01%." | 2.90 | Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial. ( Aanei, C; Aurran, T; Banos, A; Carassou, P; Cartron, G; Cymbalista, F; Dartigeas, C; de Guibert, S; Delmer, A; Dilhuydy, MS; Feugier, P; Fornecker, LM; Laribi, K; Le Garff-Tavernier, M; Leblond, V; Lepretre, S; Letestu, R; Lévy, V; Mahe, B; Michallet, AS; Nguyen-Khac, F; Orsini, F; Pegourie, B; Portois, C; Rouille, V; Salles, G; Subtil, F; Ticchioni, M; Tomowiak, C; Tournilhac, O; Truchan Graczyk, M; Villemagne, B; Vilque, JP; Ysebaert, L, 2019) |
| " We compared rates of upper digestive serious adverse events (sAEs) between TDF/FTC+EFV and TDF/FTC+ZDV patients during the first six months of treatment." | 2.78 | Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts. ( Anglaret, X; Bohoussou, F; Carrou, JL; Danel, C; Eholie, SP; Gabillard, D; Konan, R; Moh, R; Ouattara, E; Peytavin, G, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 7 (58.33) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Mato, AR | 1 |
| Ghosh, N | 1 |
| Schuster, SJ | 1 |
| Lamanna, N | 1 |
| Pagel, JM | 1 |
| Flinn, IW | 1 |
| Barrientos, JC | 1 |
| Rai, KR | 1 |
| Reeves, JA | 1 |
| Cheson, BD | 1 |
| Barr, PM | 1 |
| Kambhampati, S | 1 |
| Lansigan, F | 1 |
| Pu, JJ | 1 |
| Skarbnik, AP | 1 |
| Roeker, L | 1 |
| Fonseca, GA | 1 |
| Sitlinger, A | 1 |
| Hamadeh, IS | 1 |
| Dorsey, C | 1 |
| LaRatta, N | 1 |
| Weissbrot, H | 1 |
| Luning Prak, ET | 1 |
| Tsao, P | 1 |
| Paskalis, D | 1 |
| Sportelli, P | 1 |
| Miskin, HP | 1 |
| Weiss, MS | 1 |
| Svoboda, J | 1 |
| Brander, DM | 1 |
| Lim, KJC | 1 |
| Tam, CS | 1 |
| Lambertucci, C | 1 |
| Marucci, G | 1 |
| Dal Ben, D | 1 |
| Buccioni, M | 1 |
| Spinaci, A | 1 |
| Kachler, S | 1 |
| Klotz, KN | 1 |
| Volpini, R | 1 |
| Michallet, AS | 2 |
| Dilhuydy, MS | 2 |
| Subtil, F | 2 |
| Rouille, V | 1 |
| Mahe, B | 1 |
| Laribi, K | 1 |
| Villemagne, B | 1 |
| Salles, G | 1 |
| Tournilhac, O | 2 |
| Delmer, A | 2 |
| Portois, C | 1 |
| Pegourie, B | 1 |
| Leblond, V | 2 |
| Tomowiak, C | 1 |
| de Guibert, S | 2 |
| Orsini, F | 1 |
| Banos, A | 1 |
| Carassou, P | 1 |
| Cartron, G | 1 |
| Fornecker, LM | 2 |
| Ysebaert, L | 2 |
| Dartigeas, C | 1 |
| Truchan Graczyk, M | 1 |
| Vilque, JP | 2 |
| Aurran, T | 1 |
| Cymbalista, F | 2 |
| Lepretre, S | 1 |
| Lévy, V | 1 |
| Nguyen-Khac, F | 1 |
| Le Garff-Tavernier, M | 1 |
| Aanei, C | 1 |
| Ticchioni, M | 1 |
| Letestu, R | 1 |
| Feugier, P | 2 |
| Ouattara, E | 1 |
| Danel, C | 1 |
| Moh, R | 1 |
| Gabillard, D | 1 |
| Peytavin, G | 1 |
| Konan, R | 1 |
| Carrou, JL | 1 |
| Bohoussou, F | 1 |
| Eholie, SP | 1 |
| Anglaret, X | 1 |
| Greenup, AJ | 1 |
| Tan, PK | 1 |
| Nguyen, V | 1 |
| Glass, A | 1 |
| Davison, S | 1 |
| Chatterjee, U | 1 |
| Holdaway, S | 1 |
| Samarasinghe, D | 1 |
| Jackson, K | 1 |
| Locarnini, SA | 1 |
| Levy, MT | 1 |
| Ahn, SS | 1 |
| Chon, YE | 1 |
| Kim, BK | 1 |
| Kim, SU | 1 |
| Kim, DY | 1 |
| Ahn, SH | 1 |
| Han, KH | 1 |
| Park, JY | 1 |
| Campidelli, A | 1 |
| Lequeu, H | 1 |
| Dupuis, J | 1 |
| Ghez, D | 1 |
| Miralles Alvarez, C | 1 |
| Malan, N | 1 |
| Su, J | 1 |
| Mancini, M | 1 |
| Yang, R | 1 |
| Wirtz, V | 1 |
| Absalon, J | 1 |
| McGrath, D | 1 |
| Kumar, A | 1 |
| Betts, J | 1 |
| Barron, MJ | 1 |
| Needham, SJ | 1 |
| Schaefer, AM | 1 |
| Taylor, RW | 1 |
| Turnbull, DM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| "Phase II, Multicenter, Trial, Exploring Chemo-free Treatment (GA101+Ibrutinib) and MRD-driven Strategy in Previously Untreated Symptomatic B-chronic Lymphocytic Leukemia Medically Fit A Study From the Goelams/GCFLLC/MW Intergroup"[NCT02666898] | Phase 2 | 135 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| Benefits and Risks of Early Antiretroviral Therapy in HIV-infected Adults in Abidjan, Côte d'Ivoire: Randomized Controlled Trial (ANRS 12136 TEMPRANO)[NCT00495651] | Phase 3 | 2,073 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for adenine and Cholera Infantum
| Article | Year |
|---|---|
Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Antineoplastic Agents; Atrial Fibrillation; Benzamides | 2020 |
[Are all analogue combinations equal?].
Topics: Adenine; Anti-HIV Agents; Antimetabolites; Antiretroviral Therapy, Highly Active; Cardiovascular Dis | 2008 |
4 trials available for adenine and Cholera Infantum
| Article | Year |
|---|---|
Phase 2 study of the safety and efficacy of umbralisib in patients with CLL who are intolerant to BTK or PI3Kδ inhibitor therapy.
Topics: Adenine; Agammaglobulinaemia Tyrosine Kinase; Aged; Aged, 80 and over; Antineoplastic Agents; Cardio | 2021 |
Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial.
Topics: Adenine; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Dr | 2019 |
Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts.
Topics: Adenine; Adult; Anti-HIV Agents; CD4 Lymphocyte Count; Cote d'Ivoire; Deoxycytidine; Drug Therapy, C | 2013 |
Gastrointestinal tolerability and quality of life in antiretroviral-naive HIV-1-infected patients: data from the CASTLE study.
Topics: Adenine; Adult; Aged; Anti-Retroviral Agents; Antiretroviral Therapy, Highly Active; Atazanavir Sulf | 2010 |
6 other studies available for adenine and Cholera Infantum
| Article | Year |
|---|---|
New potent and selective A
Topics: Adenine; Adenosine A1 Receptor Antagonists; Animals; CHO Cells; Cricetulus; Gastrointestinal Disease | 2018 |
Efficacy and safety of tenofovir disoproxil fumarate in pregnancy to prevent perinatal transmission of hepatitis B virus.
Topics: Adenine; Adult; Antiviral Agents; Cohort Studies; Female; Gastrointestinal Diseases; Hepatitis B; He | 2014 |
Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Alanine Transaminase; Antiviral Agents; Cohort Studies; DNA | 2014 |
Ibrutinib in very elderly patients with relapsed/refractory chronic lymphocytic leukemia: A real-world experience of 71 patients treated in France: A study from the French Innovative Leukemia Organization (FILO) group.
Topics: Adenine; Aged; Aged, 80 and over; Antineoplastic Agents; Cardiovascular Diseases; Dose-Response Rela | 2017 |
Tenofovir disoproxil fumarate.
Topics: Adenine; Anti-HIV Agents; Drug Resistance, Viral; Drug Synergism; Gastrointestinal Diseases; HIV Inf | 2003 |
Gastrointestinal tract involvement associated with the 3243A>G mitochondrial DNA mutation.
Topics: Adenine; Adult; Base Sequence; DNA Mutational Analysis; DNA, Mitochondrial; Electron Transport Compl | 2008 |